



Corp. Off.:- 201, "The Summit Business Bay"
Behind Guru Nanak Petrol Pump,
Off Andheri Kurla Road, Andheri (E),
Mumbai - 400 093 (India)
Ph. : +91 22 69073100

14th July, 2021

BSE Limited

Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai-400001

National Stock Exchange of India Ltd.

Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai-400051

Stock Symbol-533543

Through : BSE Listing Centre

Scrip Code- BROOKS

Through : NEAPS

Dear Sir/Madam,

Ref: Outcome of Meeting of the Board of Directors of the Company held on July 13, 2021 pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("SEBI Listing Regulations"), we would like to inform you, that the Board of Directors of Brooks Laboratories Limited ('the Company') at its meeting held on July 13, 2021, has, inter alia, approved the execution of Term sheet for Joint Ventures in continuation to Marketing JVA named as SteriBrooks Penems Pvt. Ltd and Manufacturing JVA named as Brooks Steriscience Limited entered on July 22, 2020. The effects of new arrangement are as follows

Pursuant to the new arrangement the Joint Venture partner Steriscience Specialties Pvt. Ltd. will further invest Rs. 74.50 crores (Rupees Seventy Four Crores and Fifty Lakhs) in addition to Rs. 40 crores (Rupees Forty Crores), as agreed earlier vide Joint Venture agreement dated July 22, 2020, making total investment commitment of Rs. 114.50 crores (Rupees One Hundred and Fourteen Crores and Fifty Lakhs) in Brooks Steriscience Limited (Manufacturing JV). Subject to shareholders' approval, post this Investment the shareholding in Brooks Steriscience Limited will be changed to as given under

Steriscience Specialties Pvt. Ltd.-51% and
Brooks Laboratories Limited -49%.

For Brooks Laboratories Ltd.
Konkate
Company Secretary/Compliance Officer

(2)

The above mentioned JVA's entered on July 22, 2020 will become null and void and only Brooks Steriscience Limited will be effective JV after signing of the definitive agreement. All IPs/ANDAs/Dossiers of SteriBrooks Penems Pvt. Ltd. (Marketing JV) will be transferred to Brooks Steriscience Limited. The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No. CIR/CFO/CMD/4/2015 dated 9th September, 2015 are given under **Annexure 1**.


The meeting of the Board of Directors commenced at 5:30 P.M and concluded at 5:45 P.M.

We request you to kindly take this in your record.

Thanking you,

Yours Sincerely

For **BROOKS LABORATORIES LIMITED**




Jyoti Sancheti

(Company Secretary and Compliance Officer)

ANNEXURE – 1

Details as per the Securities and Exchange Board of India circular no.CIR/CFD/CMD/4/2015 dated September 9, 2015

Sr. No.	Particulars	Restructuring											
a.	Details and reasons for restructuring	<p>The details of shareholding of JV partners in Brooks Steriscience Limited as given under</p> <table border="1" data-bbox="743 584 1419 981"> <thead> <tr> <th data-bbox="743 584 943 701">JV</th> <th data-bbox="943 584 1192 701">Existing Shareholding %</th> <th data-bbox="1192 584 1419 701">New Shareholding %</th> </tr> </thead> <tbody> <tr> <td data-bbox="743 701 943 819">Brooks Laboratories Ltd. (BLL)</td> <td data-bbox="943 701 1192 819">73.33</td> <td data-bbox="1192 701 1419 819">49</td> </tr> <tr> <td data-bbox="743 819 943 981">Steriscience Specialties Pvt. Ltd. (SSPL)</td> <td data-bbox="943 819 1192 981">26.67</td> <td data-bbox="1192 819 1419 981">51</td> </tr> </tbody> </table> <p>By this new arrangement fresh investment will be infused by strategic JV Partner SSPL for backward and forward integration.</p>			JV	Existing Shareholding %	New Shareholding %	Brooks Laboratories Ltd. (BLL)	73.33	49	Steriscience Specialties Pvt. Ltd. (SSPL)	26.67	51
JV	Existing Shareholding %	New Shareholding %											
Brooks Laboratories Ltd. (BLL)	73.33	49											
Steriscience Specialties Pvt. Ltd. (SSPL)	26.67	51											
b.	Quantitative and/ or Qualitative effect of restructuring	The new investments will be deployed to set up a dedicated Ertapenem formulation facility and integrate the APIs for all the four carbapenems under development:											
c.	Details of benefit, if any, to the promoter/promoter group/group companies from such proposed restructuring	NIL											
d.	Brief details of change in shareholding pattern (if any)of all entities	<p>The proposed shareholding in Brooks Steriscience Limited will be as given under</p> <p>Steriscience Specialties Pvt. Ltd. -51% and Brooks Laboratories Limited -49%.</p>											

For Brooks Laboratories Ltd.

 Company Secretary/Compliance Officer